SEC Filing Summary: Owens & Minor, Inc. Form 10-Q
Issuer discrepancy: The request identifies Accendra Health Inc., but the supplied filing is for Owens & Minor, Inc. (NYSE: OMI). This summary reflects the filing provided.
Business context and reporting period
The filing reports the quarter and nine months ended September 30, 2020. Owens & Minor operates Global Solutions, including U.S. distribution and logistics, and Global Products, which manufactures and sources medical-surgical products. Movianto, its European logistics business, was sold on June 18, 2020 and is presented as discontinued operations.
Financial results and liquidity
| Metric | Q3 2020 | Q3 2019 | Nine months 2020 | Nine months 2019 |
|---|---|---|---|---|
| Net revenue | $2,187.9 million | $2,292.8 million | $6,118.3 million | $7,020.3 million |
| Gross margin | $344.3 million; 15.74% | $280.6 million; 12.24% | $882.3 million; 14.42% | $843.8 million; 12.02% |
| Operating income | $75.6 million | $26.1 million | $108.5 million | $58.6 million |
| Continuing-operations income (loss) | $46.1 million | $3.4 million | $37.3 million | $(17.2) million |
| Net income (loss) | $46.1 million | $1.2 million | $(20.9) million | $(23.3) million |
| Continuing-operations diluted EPS | $0.76 | $0.06 | $0.61 | $(0.28) |
For the nine months, discontinued operations recorded a $58.2 million after-tax loss, including a $65.5 million divestiture loss. Net revenue fell 4.6% in Q3 and 12.8% year to date. Global Solutions revenue declined 8.9% and 16.6%, respectively; Global Products revenue increased 31.7% and 15.4%.
Operating cash flow was $268.2 million for the first nine months, versus $139.1 million a year earlier. Investing cash flow provided $112.8 million, including $133.0 million of Movianto sale proceeds; financing used $245.0 million. Cash and cash equivalents at September 30 were $77.3 million; cash, cash equivalents and restricted cash totaled $227.5 million.
Total debt was $1.329 billion, compared with $1.560 billion at December 31, 2019. Long-term debt was $1.100 billion; current maturities were $229.1 million. The company had $316.1 million available under its $400 million revolver and was in compliance with debt covenants. Accounts receivable were $688.9 million, inventory $1.095 billion, and accounts payable $946.1 million.
Material changes and management commentary
- COVID-19 reduced elective procedures and distribution activity, while increased demand for personal protective equipment (PPE), favorable product mix and improved manufacturing productivity supported Global Products results and gross margins.
- Management said Global Solutions operating income declined as a result of lower revenue, including reduced elective surgeries and customer non-renewals. Global Products operating income rose substantially, attributed to PPE demand, favorable mix and operating efficiencies.
- The company sold Movianto for $133 million in cash and recorded a $65.5 million loss. A final working-capital adjustment could provide a benefit of up to $42 million; none was recorded at September 30.
- On October 6, the company completed an equity offering, including the exercised underwriters’ option, for approximately $190 million of net proceeds. It used proceeds to repay $109 million of Term Loan A-1, $52 million of Term Loan A-2 and $30 million of revolver borrowings. It also announced redemption of all remaining 2021 Notes for November 30, 2020.
Outlook, risks and contingencies
The filing provides no quantified revenue or earnings guidance. Management said it could not predict the pandemic’s duration or full financial impact, and cautioned that PPE growth and related operational benefits may not continue. Risks include elective-procedure trends, customer and supplier performance, competition and pricing pressure, raw-material and fuel costs, foreign exchange, and the company’s substantial debt and refinancing needs. Credit agreements and notes include cross-default provisions and springing maturities.
The IRS proposed adjustments to the company’s 2015 and 2016 tax returns concerning transfer pricing. The company disputes the IRS position and believes its reserve is adequate, but stated that an adverse outcome could materially affect financial results or cash flows. The filing also notes a $30 million anticipated Defense Production Act investment agreement for N-95 capacity expansion; approximately $20.4 million had been expended and reimbursed by September 30.
Important facts for investors to verify
- Confirm the issuer: the supplied filing is Owens & Minor, not Accendra Health.
- Track elective-surgery recovery and whether PPE demand, product mix and manufacturing efficiencies persist.
- Review the completed post-quarter debt repayments and redemption of the 2021 Notes, including remaining debt and liquidity after those transactions.
- Monitor the Movianto working-capital adjustment and the IRS tax dispute, including any changes to reserves or potential exposure.
- Reconcile share counts: the filing reports 63.716 million shares at September 30, while its cover reports 73,512,279 shares outstanding on October 29, following the subsequent equity offering.